SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis
JAMA Network Open · 18.03.2024 · 7 (3) · e242744
DOI: 10.1001/jamanetworkopen.2024.2744 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 18.03.2024. Verfasst von Mahesh M Umapathysivam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 1, Diabetic Ketoacidosis, Ketosis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
This cohort study examines the natural history and response to treatment of sodium glucose cotransporter 2 (SGLT2) inhibitor–associated ketoacidosis compared with that of type 1 diabetes–associated ketoacidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide, South Australia, Australia.
- Endocrine Department, Queen Elizabeth Hospital, Woodville, South Australia, Australia.
- Endocrine Department, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
- Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.
- Anaesthetic Department, Queen Elizabeth Hospital, Woodville, South Australia, Australia.
Zitieren
APA
Umapathysivam, M. M., Morgan, B., Inglis, J. M., Meyer, E., Liew, D., Thiruvenkatarajan, V., & Jesudason, D. (2024). SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis. JAMA Network Open, 7(3), e242744. https://doi.org/10.1001/jamanetworkopen.2024.2744
Vancouver
Umapathysivam MM, Morgan B, Inglis JM, Meyer E, Liew D, Thiruvenkatarajan V, et al. SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis. JAMA Network Open. 2024;7(3):e242744. doi:10.1001/jamanetworkopen.2024.2744
BibTeX
@article{Umapathysivam2024,
author = {Umapathysivam, Mahesh M and Morgan, Bethany and Inglis, Joshua M and Meyer, Emily and Liew, Danny and Thiruvenkatarajan, Venkatesan and Jesudason, David},
title = {SGLT2 Inhibitor–Associated Ketoacidosis vs Type 1 Diabetes–Associated Ketoacidosis},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {3},
pages = {e242744},
doi = {10.1001/jamanetworkopen.2024.2744}
}
EUVIMED